To explore the potential of LOXL2 as a biomarker in glioma and construct a genomic integrated clinical prognostic model
BackgroundGlioma is a common invasive tumor of the central nervous system, and its pathological features significantly impair the quality of life of patients, with high mortality risk and easy recurrence. For glioma Lysine Oxidase 2(LOXL2), there are few reports in the scholarly literature. Based on...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1602475/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|